Study of LM-299 for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older and willing to sign a consent form.
- You should have advanced solid tumors that have not responded to standard treatment, or standard treatment is not suitable for you.
- You need to have a tumor sample (from a past biopsy or a new one) available for testing.
- You must be able to do most daily activities on your own (ECOG 0-1).
- You cannot have cancer that has spread to your brain or the lining around your brain.
- You must not have certain other medical conditions like uncontrolled bleeding, severe infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
This trial tests a new drug called LM-364, either by itself or combined with other anti-cancer treatments. The goal is to see if it can help people with advanced solid tumors that have not responded to standard therapies.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Hear when a new Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.